Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Assets: 2021-2024

Historic Assets for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $351.2 million.

  • ARS Pharmaceuticals' Assets rose 71.32% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.8 million, marking a year-over-year increase of 71.32%. This contributed to the annual value of $351.2 million for FY2024, which is 50.59% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Assets of $351.2 million as of FY2024, which was up 50.59% from $233.2 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Assets peaked at $351.2 million during FY2024, and registered a low of $61.4 million during FY2021.
  • For the 3-year period, ARS Pharmaceuticals' Assets averaged around $288.6 million, with its median value being $281.4 million (2022).
  • In the last 5 years, ARS Pharmaceuticals' Assets spiked by 358.02% in 2022 and then dropped by 17.14% in 2023.
  • ARS Pharmaceuticals' Assets (Yearly) stood at $61.4 million in 2021, then surged by 358.02% to $281.4 million in 2022, then declined by 17.14% to $233.2 million in 2023, then surged by 50.59% to $351.2 million in 2024.